
|Articles|May 12, 2008
Irritable bowel syndrome gains new treatment
Amitiza has gained a new indication-to treat irritable bowel syndrome with constipation in women.
Advertisement
Amitiza (lubiprostone), formerly approved to treat chronic idiopathic constipation, has gained clearance for a new indication. The drug can now be used to treat irritable bowel syndrome with constipation (IBS-C) in adult women. According to Sucampo Pharmaceuticals and Takeda Pharmaceuticals America, the product is the only approved treatment for IBS-C in this country.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Addressing Depression Symptoms Can Significantly Improve Asthma Outcomes
2
President Trump Signs Sweeping, Unprecedented Federal PBM Reform
3
TrumpRx Officially Launches, Introduces Drug Prices
4
Q&A: PBMs, Community Pharmacy’s Next Move Following PBM Reform Signing
5























